Monte Rosa Therapeutics, Inc. (GLUE) stock
Close on Nov 12, 2026Market cap $794.27MP/E –Yield –
Monte Rosa Therapeutics, Inc. saw revenue fall 61.3% to $70.33M over the twelve months to Sep 30, 2026. Operating income fell 1872.0% to -$150.82M, moving the operating margin from 4.7% to -214.5%. Free cash flow was -$174.39M, down 220.3% from a year earlier. At the latest close the market valued the company at $794.27M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $794.27M
- P/E ratio
- –
- Price to sales
- 11.29
- Price to book
- 1.60
- Dividend yield
- –
- Free cash flow yield
- -21.96%
Fundamentals
- Revenue
- $70.33M
- Net income
- -$130.95M
- EPS, diluted
- -$1.40
- Free cash flow
- -$174.39M
- Book value per share
- $4.57
- Diluted shares
- 109M
Trading
- Next earnings
- Mar 16, 2027 (estimated, before the open)
- Previous close
- $10.31
- Open
- $10.17
- Day's range
- $9.28 – $10.28
- Volume
- 1,245,710
- Average volume (20 days)
- 1,400,951
- Index membership
- Russell 2000 (since Sep 2021), Russell 3000 (since Aug 2021)
- Beta (5 years)
- 1.83
- 52-week range
- $9.28 – $25.77
- RSI (14 days)
- 32.4
- Volatility (1 year)
- 80.0%
- Relative volume
- 0.91×
- WACC
- 14.0%
On 2 of our idea lists: More cash than they're worth, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | GLUE | S&P 500 | Difference | GLUE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -11.5% | -2.7% | −8.8 pts | ||
| 3 months | -41.6% | -1.7% | −39.9 pts | ||
| Year to date | -40.6% | +11.9% | −52.5 pts | ||
| 1 year | -34.3% | +12.0% | −46.2 pts | ||
| 3 years | +190.0% | +78.2% | +111.9 pts | +42.6% | +21.2% |
| 5 years | -63.0% | +73.2% | −136.3 pts | -18.1% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Monte Rosa Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Results
- Results
About Monte Rosa Therapeutics
Biological Products, (No Diagnostic Substances)
Monte Rosa Therapeutics is a clinical-stage biotechnology company that develops molecular glue degraders to selectively eliminate disease-associated proteins using cellular degradation mechanisms. The company designs small molecule therapies across immunology, inflammation, cardiology, and oncology through its proprietary QuEEN discovery platform. Its clinical-stage pipeline includes MRT-6160 for immune-mediated diseases, MRT-8102 for inflammasome-driven inflammatory conditions, and MRT-2359 for metastatic castration-resistant prostate cancer. Because the company currently has no commercial product sales, its primary counterparties are pharmaceutical collaborators, such as Novartis and Roche, which license and develop its drug candidates.
Company profile, executives and historyMonte Rosa Therapeutics stock: common questions
What is Monte Rosa Therapeutics's stock price?
GLUE closed at $9.31 on Nov 12, 2026, down 9.70% on the day. Over the past 52 weeks it traded between $9.28 and $25.77.
What is Monte Rosa Therapeutics's market cap?
Monte Rosa Therapeutics was worth $794.27M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is GLUE's P/E ratio?
Monte Rosa Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.40), so it has no meaningful P/E ratio.
How much revenue does Monte Rosa Therapeutics make?
Monte Rosa Therapeutics reported revenue of $70.33M for the twelve months to Sep 30, 2026, down 61.3% from a year earlier.
Does Monte Rosa Therapeutics pay a dividend?
No. Monte Rosa Therapeutics has not paid a cash dividend over the last twelve months.
When does Monte Rosa Therapeutics report earnings next?
Monte Rosa Therapeutics is expected to report Q4 FY2026 results on Mar 16, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has GLUE stock performed over the past year?
Including dividends, GLUE returned -34.3% over the past year, against +12.0% for the S&P 500.
How many GLUE shares are sold short?
21M shares were sold short at the latest FINRA report, 27.63% of the float, or 15.7 days of average trading volume.
Who are Monte Rosa Therapeutics's competitors?
Companies most similar to Monte Rosa Therapeutics by business, industry and size include KYMR, STRO, BDTX, CCCC, CGEN.
See a number that looks wrong?